PROFOUND MEDICAL CORP. Cost of Revenue
PROFOUND MEDICAL CORP. (PROF) reported Cost of Revenue of $536.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-06
- PROFOUND MEDICAL CORP. cost of revenue for the quarter ending 2026-06-30 was $536.00K, a 9.61% decline year-over-year.
- PROFOUND MEDICAL CORP. cost of revenue for the quarter ending 2026-03-31 was $1.50M, a 95.96% increase year-over-year.
- PROFOUND MEDICAL CORP. cost of revenue for the quarter ending 2025-12-31 was $1.99M, a 63.59% increase year-over-year.
- PROFOUND MEDICAL CORP. cost of revenue for the quarter ending 2025-09-30 was $1.36M, a 30.08% increase year-over-year.
- PROFOUND MEDICAL CORP. cost of revenue for fiscal 2025 was $4.71M, a 29.15% increase from fiscal 2024.
- PROFOUND MEDICAL CORP. cost of revenue for fiscal 2024 was $3.64M, a 26.19% increase from fiscal 2023.
- PROFOUND MEDICAL CORP. cost of revenue for fiscal 2023 was $2.89M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $536.00K 10-Q · filed 2026-08-06 | $2.04M 10-Q · filed 2026-08-06 | $4.03M derived: sum of 3 quarters · filed 2026-08-06 | $5.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-07 | $3.49M derived: sum of 2 quarters · filed 2026-05-07 | $4.85M derived: sum of 3 quarters · filed 2026-05-07 | $5.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.34M derived: sum of 2 quarters · filed 2026-03-05 | $3.94M derived: sum of 3 quarters · filed 2026-08-06 | $4.71M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.36M 10-Q · filed 2025-11-13 | $1.95M derived: sum of 2 quarters · filed 2026-08-06 | $2.72M 10-Q · filed 2025-11-13 | $3.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $593.00K 10-Q · filed 2026-08-06 | $1.36M 10-Q · filed 2026-08-06 | $2.58M derived: sum of 3 quarters · filed 2026-08-06 | $3.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $768.00K 10-Q · filed 2026-05-07 | $1.98M derived: sum of 2 quarters · filed 2026-05-07 | $3.03M derived: sum of 3 quarters · filed 2026-05-07 | $3.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.26M derived: sum of 2 quarters · filed 2026-03-05 | $3.07M derived: sum of 3 quarters · filed 2026-03-05 | $3.64M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.04M 10-Q · filed 2025-11-13 | $1.86M derived: sum of 2 quarters · filed 2025-11-13 | $2.43M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $812.00K 10-Q · filed 2025-08-14 | $1.39M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $573.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $2.89M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |